CR20160339A - ANTI-VISTA ANTIBODIES AND FRAGMENTS - Google Patents
ANTI-VISTA ANTIBODIES AND FRAGMENTSInfo
- Publication number
- CR20160339A CR20160339A CR20160339A CR20160339A CR20160339A CR 20160339 A CR20160339 A CR 20160339A CR 20160339 A CR20160339 A CR 20160339A CR 20160339 A CR20160339 A CR 20160339A CR 20160339 A CR20160339 A CR 20160339A
- Authority
- CR
- Costa Rica
- Prior art keywords
- fragments
- methods
- vista antibodies
- vista
- melanomas
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 230000006044 T cell activation Effects 0.000 abstract 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a nuevos anticuerpos y fragmentos que se unen al dominio V de la Ig supresora de la activación de linfocitos T (VISTA), y métodos para preparar y usar los mismos. Los métodos de uso incluyen métodos de tratamiento del cáncer, incluyendo leucemias, linfomas, tumores sólidos y melanomas.The present invention relates to new antibodies and fragments that bind to the V domain of the T-cell activation suppressor Ig (VISTA), and methods for preparing and using them. Methods of use include methods of cancer treatment, including leukemia, lymphomas, solid tumors and melanomas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920695P | 2013-12-24 | 2013-12-24 | |
| US201461085086P | 2014-11-26 | 2014-11-26 | |
| PCT/IB2014/002868 WO2015097536A2 (en) | 2013-12-24 | 2014-12-22 | Anti-vista antibodies and fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20160339A true CR20160339A (en) | 2016-10-05 |
Family
ID=59676281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20160339A CR20160339A (en) | 2013-12-24 | 2014-12-22 | ANTI-VISTA ANTIBODIES AND FRAGMENTS |
Country Status (1)
| Country | Link |
|---|---|
| CR (1) | CR20160339A (en) |
-
2014
- 2014-12-22 CR CR20160339A patent/CR20160339A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP16062894A (en) | ANTIBODIES AND ANTI-VISION FRAGMENTS | |
| BR112016007891A2 (en) | use of cbp / ep300 bromodomain inhibitors for cancer immunotherapy | |
| MX2021013520A (en) | Methods of treating cancers using pd-1 axis binding antagonists and taxanes. | |
| CR20160500A (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
| CO2017010618A2 (en) | Antibodies against icos | |
| CL2016002667A1 (en) | Novel anti-rnf43 antibodies and methods for use | |
| MX2017016647A (en) | ANTIBODIES AND ANTI-VISTA FRAGMENTS. | |
| UY36452A (en) | NEW MODULATING FXR COMPOUNDS (NR1H4) | |
| BR112016017256A2 (en) | combination of a pd-1 antagonist and a vegfr inhibitor for cancer treatment | |
| UY36445A (en) | FXR MODULATING COMPOUNDS (NR1H4 CONTAINING HYDROXY GROUPS) | |
| CL2016000388A1 (en) | Composition of 6 mRNA coding for 5t4 (tpbg, survivin (birc5), ny-eso-1 (ctag1b), mage-c1, mage-c2 and muc1 and vaccine to make a useful medication to treat lung cancer | |
| UY35500A (en) | INDAZOLS REPLACED WITH HETEROARILO | |
| MX384909B (en) | AN ANTI-TAU ANTIBODY FOR USE IN TREATING TAUOPATHY. | |
| CO2017003005A2 (en) | Anti-mfi2 antibodies | |
| MX2018005544A (en) | USE OF AGONISTS OF THE TOLL-8 TYPE RECEPTOR (TLR8) TO TREAT CANCER. | |
| BR112016029842A2 (en) | anti-cd22-drug antibody conjugates and methods of use | |
| BR112016017112A2 (en) | APILIMOD COMPOSITIONS AND METHODS OF USE THEREOF | |
| CL2016000038A1 (en) | Pyroxolo-substituted pyridinamines | |
| MX2017010002A (en) | COMBINATION THERAPIES. | |
| BR112019023742A2 (en) | anti-trkb antibodies | |
| JOP20150008B1 (en) | Anti-vista antibodies and fragments | |
| EA201591709A1 (en) | 5-BROMED INDIRUBINES | |
| UY35823A (en) | NMDA ANTAGONIST PROPHARMS | |
| CR20160339A (en) | ANTI-VISTA ANTIBODIES AND FRAGMENTS | |
| JOP20200184A1 (en) | Anti-VISTA Antibodies And Fragments |